R3 Vascular
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1145 Terra Bella Ave, Mountain View, Cal...Website
www.r3vascular.comRevenue
$8.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About R3 Vascular
Based out of Mountain View, California, R3 Vascular is an early-stage medical device company and bioresorbable vascular scaffolds (BVS) technology platform provider.Explore more
R3 Vascular Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is R3 Vascular your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if R3 Vascular had a recent Job posting/layoffs
R3 Vascular, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when R3 Vascular launches new products
Congratulate Masked Content for being promoted to Masked Content at R3 Vascular
Website visits: Recent activity has been detected on your website
Check out if R3 Vascular is spiking on competitors!
Funding: Get notified immidiatlly once R3 Vascular has new funding data
Check if R3 Vascular has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on R3 Vascular recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined R3 Vascular as Masked Content
Find 2 more new buyers
Compare Similar Companies to R3 Vascular
Compare insights from companies similar to R3 Vascular, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$9.3M
11-50
Private
$115M
2010
AK
Alexander KhairkhahanInventor, Founder, Chief Operating Officer, General Manager
Company Profile Activity
Activity Insights
R3 Vascular is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
R3 Vascular is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about R3 Vascular.
R3 Vascular financials insights
Gather financial insights about R3 Vascular, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$17.8M
2024
Other Financing Round
$87M
R3 Vascular Tech Stack
A closer look at the technologies used by R3 Vascular
Most Recent Scoops
Funding
Funding
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move
R3 Vascular News & Media
R3 Vascular Secures WCG IRB Approval and CMS Category B Medicare Coverage for the ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
MOUNTAIN VIEW, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce that it received WCG Institutional Review Board (IRB) approval for the ELITE-BTK Pivotal Trial of its MAGNITUDE Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease (PAD). This approval allows the triR3 Vascular secures investigational device exemption for PAD treatment
The R3 Vascular investigational device exemption will be used to launch a pivotal trial of its treatment for peripheral arterial disease.FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce that the U.S. Food and Drug Administration (FDA) granted investigational device exemption (IDE) approval to initiate its ELITE-BTK pivotal trial of its next generation drug eluting bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD.R3 Vascular Appoints Josh Smale as its Vice President of Global Clinical and Scientific Affairs
R3 Vascular Inc. is pleased to announce the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding R3 Vascular
Sign Up For FreeTo access detailed company insights
Based out of Mountain View, California, R3 Vascular is an early-stage medical device company and bioresorbable vascular scaffolds (BVS) technology platform provider.... Read More
